If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
16/02/2026 [06:47:00]
Absstract of: US20260041754A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.
Absstract of: US20260041670A1
The present disclosure discloses drugs for preventing and/or treating Alzheimer's disease (AD). A CF3CN derivative provided by present disclosure has any one of structural formulas 1-4 shown below. All four CF3CN derivatives have TrkB agonist activities; and specifically, the CF3CN derivative shown in formula 2 serves as an optimal derivative. In vivo PK studies reveal that the CF3CN derivative shown in the formula 2 is capable of improving a B/P Ratio of CF3CN, and overcoming the limitations of CF3CN. Nanoparticles are prepared by encapsulating the CF3CN derivatives with zein and lactoferrin, which may further enhance an oral bioavailability and a brain drug concentration, thereby improving AD treatment effects. By further improving the formulation and administration route, a liposome is employed to encapsulate the CF3CN derivative for both oral and intranasal administration, which effectively solves the problems of low bioavailability and low brain drug concentration of the derivative.
Absstract of: US20260041644A1
Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, I to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.
Absstract of: US20260041645A1
The present invention relates to compositions and methods for delivery of therapeutic agent. In certain aspects, the invention comprises a metal-organic framework nanoparticle encapsulating a protein. In some aspects, the metal-organic framework nanoparticle encapsulating a protein is coated with an extracellular vesicle membrane.
Absstract of: US20260041647A1
Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and/or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and/or an autoimmune diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and/or other targets in subject.
Absstract of: US20260041638A1
The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.
Absstract of: US20260042787A1
The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams.The present invention relates, inter alia, to a new ultra-microporous crystalline metal organic framework solid (comprising bisphosphonic acid ligands (also referred to as Phosphonate MOF), such as MIP-210(M) and uses thereof as a carrier in Lewis-based gas (such as NO) delivery. The invention also relates to controlled release of the Lewis-based gas in wounds, for example by topical application. The invention also encompasses a synthetic method for producing the new ultra-microporous crystalline metal organic framework solid of the invention.The MOFs of the present invention can be used in various applications such as gas carrier and/or for the controlled release of gas. The MOFs of the present invention thus are very versatile and have therapeutic and non therapeutic applications.
Absstract of: AU2024316257A1
Excipient granulations containing a viscosifying agent, a disintegrant, and one or more additional excipients are disclosed. An excipient granulation can be combined with a pharmaceutical granulation to provide a pharmaceutical composition. The excipient granulations can be used to increase the viscosity of an aqueous composition such as an oral pharmaceutical composition. When added to an aqueous solution, the excipient granulation can dissolve to provide a suspension of the pharmaceutical granules in a viscous solution. The excipient granulation can be used to improve the palatability of oral pharmaceutical compositions containing a pharmaceutical granulation.
Absstract of: AU2025270991A1
The present disclosure relates to methods and compositions comprising derivatized-chitosan polyplexes reversibly coated with a polyanion-containing block co-polymer for the localized expression of IL-12 in mucosal tissues, preferably in combination with an IFN- 1 activator/inducer, for use in cancer immunotherapy. ov o v
Absstract of: AU2024322403A1
The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject. The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.
Absstract of: AU2024310306A1
The present invention provides, in part, dianhydrohexitol-based cationic lipids of Formula (I), and sub-formulas thereof: (I), or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formula (II), and sub-formulas thereof: (II), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: AU2024316257A1
Excipient granulations containing a viscosifying agent, a disintegrant, and one or more additional excipients are disclosed. An excipient granulation can be combined with a pharmaceutical granulation to provide a pharmaceutical composition. The excipient granulations can be used to increase the viscosity of an aqueous composition such as an oral pharmaceutical composition. When added to an aqueous solution, the excipient granulation can dissolve to provide a suspension of the pharmaceutical granules in a viscous solution. The excipient granulation can be used to improve the palatability of oral pharmaceutical compositions containing a pharmaceutical granulation.
Absstract of: AU2024310332A1
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: WO2026036007A1
The present invention provides a pharmaceutical-acceptable lipid nanoparticle (LNP) composition for delivering active agents to the bone marrow. The LNP comprises a ganglioside, a cholesterol, a phospholipid, and a cationic or ionizable lipid and exhibits superior transfection efficiency in bone marrow cells relative to other lipid nanoparticles that lack the ganglioside.
Absstract of: EP4691500A2
An object of the present invention is to provide a lipid composition capable of realizing an excellent nucleic acid delivery efficiency. According to the present invention, there is provided a lipid composition containing a compound represented by Formula (1), a lipid represented by Formula (2) or a salt of the lipid, a neutral lipid, a nonionic hydrophilic polymer, and a lipid having a nucleic acid.The definition of each symbol in the formulae is as described in the present specification.
Absstract of: CN120826371A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular a source of ions of K; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of K, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing the composition/solutions 1 and 2 and standing under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating said nanoparticles formed. According to the invention, both the first composition/solution 1 and the second composition/solution 2 consist of said source and an aqueous buffer. The invention also relates to colloidal suspensions of the resulting nanoparticles, and to pharmaceutical compositions comprising said nanoparticles.
Absstract of: WO2024201468A1
Methods, kits and material composition for use in correction of eye condition are disclosed. This includes a selected three-dimensional patterning on the surface of a cornea of a user. The pattern is selected to provide an optical effect in accordance with a predetermined vision impediment of the user. A dispersion, in the form of a liquid (aqueous solution) comprising nanoparticles, is applied onto said selected three- dimensional pattern such that the nanoparticles are dispersed in incision regions of the pattern. The nanoparticles comprise biocompatible protein based nanoparticles. The dispersion may be used as eye drops thereby allowing the nanoparticles to occupy the etching regions on the cornea, thereby functionalizing and maintaining the visual correction effect of eye condition by said pattern. The present disclosure further provides a method and a kit for ablating the corneal tissue in a selected pattern by using a visual spectrum illumination.
Absstract of: CN120916750A
The present invention relates to an oil-in-water nanoemulsion substantially free of propylene glycol. The nanovesicle formulations are particularly stable in shelf life at different storage temperatures.
Absstract of: AU2024254671A1
The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.
Absstract of: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Absstract of: WO2024209013A1
The present invention relates to the field of lipid nanoparticles (LNPs). In particular, the present invention relates to an LNP composition comprising a cationic or cationically ionisable lipid or lipid-like material, a helper lipid, a lipopolymer, and a monomycoloyl glycerol (MMG) analogue. The LNP composition is particularly useful as a vaccine composition.
Absstract of: WO2024200823A1
The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain capable of specifically binding to a target expressed on activated immune cells surface and one or several mRNA molecule(s) encoding an activity-enhancing protein of said activated immune cells, and to uses thereof.
Absstract of: AU2024254671A1
The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.
Absstract of: WO2024211865A2
The current disclosure relates to lipid-based compositions and methods of administering therapeutic agents relating thereto. In particular, the disclosure relates to lipid-like substituted aryl and/or heteroaryl compounds, substituted piperazines, and/or other aryl and/or heteroaryl lipid compounds as LNP delivery materials that may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to tissues of a subject.
Nº publicación: EP4687964A2 11/02/2026
Applicant:
PURDUE RESEARCH FOUNDATION [US]
Purdue Research Foundation
Absstract of: WO2024207006A2
A method of prophylactically or therapeutically vaccinating a subject for cancer comprising administering to the subject an immune response-inducing effective amount of a composition comprising (a) an agonist of the stimulator of interferon (IFN) genes (STING) and (b) a tumor (or cancer) antigen or neoantigen, both (a) and (b) of which are adsorbed onto cationic phytoglycogen (PG) nanoparticles; a microneedle device (e.g., microneedle patch) comprising a plurality of microneedles on/in which are contained cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or a neoantigen; a needle-free injector comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen; and a kit comprising (a) a microneedle device or a needle-free injector and (b) a composition comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen.
BOPI
Electronic site
